Observational studyInternational journal of clinical oncology2023
The prognostic role of systemic inflammatory markers in apparent early-stage ovarian cancer.
Observational study in International journal of clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prognostic significance of systemic immune inflammation index for ovarian cancer: An updated systematic review and meta-analysis.Journal of ovarian research · 2025Pooled it
- Knowledge graph and bibliometric analysis of inflammatory indicators in ovarian cancer.Frontiers in oncology · 2025Pooled it
- Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives Prognosis.Annals of surgical oncology · 2026Review
- Systemic Immune-Inflammatory Biomarkers in Epithelial Ovarian Cancer: Subgroup-Dependent Prognostic Performance and Integrated Risk Stratification.International journal of molecular sciences · 2026Article
- Systemic inflammatory markers are associated with neoadjuvant chemotherapy selection but not survival in advanced serous epithelial ovarian cancer.Irish journal of medical science · 2026Article
- Preoperative Pan-Immune-Inflammation Value for the Differential Diagnosis and Prognostic Assessment of Ovarian Tumors: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- CA-125/albumin and lymphocyte/albumin ratios as complementary biomarkers to the malignancy risk index in ovarian cancer.Scientific reports · 2025Article
- Taxonomic Profiling of Systemic Inflammatory Parameters as Predictors of Tumor Progression in Primary Colorectal Cancer.Journal of clinical medicine · 2025Article
- Article
- Association of lymphocyte-to-C-reactive protein ratio with all-cause and cause-specific mortality among US cancer survivors.European journal of medical research · 2025Article
- Prognostic significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in uterine carcinosarcoma.International journal of clinical oncology · 2025Article
- The impact of preoperative immunonutritional status on prognosis in ovarian cancer: a multicenter real-world study.Journal of ovarian research · 2025Article
- Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.The oncologist · 2025Review
- Dynamic changes in prognostic nutritional index and systemic immune-inflammation index predict survival following debulking surgery in ovarian cancer.Frontiers in oncology · 2025Article
- Interleukin 1 family dysregulation in serum and peritoneal fluid of ovarian cancer patients - potential clinical implications.Frontiers in oncology · 2025Article
- A Review of the Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Nonhematologic Malignancies.Diagnostics (Basel, Switzerland) · 2024Review
- The Influence of Inflammatory and Nutritional Status on the Long-Term Outcomes in Advanced Stage Ovarian Cancer.Cancers · 2024Article
- Significance of Pretreatment Hemoglobin-Albumin-Lymphocyte-Platelet Index for the Prediction of Suboptimal Surgery in Epithelial Ovarian Cancer.World journal of oncology · 2024Article
- Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy.Gynecologic oncology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies analyzed the prognostic role of systemic inflammatory markers in early-stage ovarian cancer. The primary endpoint of the present study was to assess the prognostic impact of baseline inflammatory markers in early-stage ovarian cancer. The secondary endpoints were to compare the disease-free survival (DFS) of inflammatory markers with standard risk factors and to correlate these with BRCA mutational status.
methodsRetrospective, single-center, observational study. Patients with FIGO-stage I-II and IIIA1 epithelial ovarian cancer undergoing primary surgery between 10/2012 and 12/2019 were included. Inflammatory markers were evaluated on the results of the complete blood count and coagulation tests, performed before ovarian cancer surgery. The Receiver Operating Characteristic curve was used to determine the optimal cut-off value of different baseline inflammatory biomarkers for the DFS analysis.
resultsThree hundred fifty-nine patients were included in the study period. Baseline neutrophil-lymphocyte ratio (NLR) ≥ 3 and systemic immune inflammation index (SII, defined as platelet x neutrophil-lymphocyte ratio) ≥ 1000 were associated with worse 3 year DFS and baseline SII ≥ 1000 was associated with worse 3 year OS. BRCA-mutated patients with SII ≥ 1000 and with NLR ≥ 3 had significantly worse DFS compared to SII < 1000 and with NLR < 3. FIGO stage > I was the only independent risk factor for higher risk of recurrence.
conclusionSII ≥ 1000 and NLR ≥ 3 were associated with worse 3 year DFS and SII ≥ 1000 was associated with worse 3 year OS. The subgroups of BRCA-mutated patients with higher inflammation markers (SII ≥ 1000 and NLR ≥ 3) were associated with worse DFS. These findings might be helpful to design personalized treatment and more intensive surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.